|

Selinexor Clinical Trials

21 actively recruiting trials across 11 locations

No change since June 2026

Also known as: ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, Gemcitabine, KPT 330, KPT-330 +10 more

Pipeline

Phase 1: 2Phase 2: 9Phase 3: 3Phase 1/2: 6

Top Sponsors

National Cancer Institute (NCI)3
Karyopharm Therapeutics Inc2
Washington University School of Medicine1
University of Rochester1
University of Miami1

Indications

Cancer21
Multiple Myeloma4
Multiple Myeloma, Refractory2
Recurrent MGMT-Methylated Glioblastoma1
Pancreatic Ductal Carcinoma1

Other8 trials

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Phase 2

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2

Second-line Immunotherapy for ES-SCLC

N/A

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Phase 1/2

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3

Using Tumor Models to Determine Treatments

Phase 2

Birmingham, Alabama2 trials

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Children's Hospital of Alabama

Phase 1/2

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Los Angeles, California2 trials

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Children's Hospital of Los Angeles (Data Collection Only)

Phase 2

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

Keck Medicine of USC Koreatown

Phase 2

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Phoenix, Arizona1 trial

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Mayo Clinic Hospital in Arizona

Phase 1/2

West Hollywood, California1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Berenson Cancer Center

Phase 1

Coral Gables, Florida1 trial

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

University of Miami, Lennar Foundation Medical Center

Phase 2

Atlanta, Georgia1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Children's Healthcare of Atlanta

Phase 1/2

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

St Louis, Missouri1 trial

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Washington University School of Medicine

Phase 1

Rochester, New York1 trial

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

University of Rochester

Phase 2

Madison, Wisconsin1 trial

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

University of Wisconsin

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.